The Globe and Mail reports in its Wednesday, May 12, edition that CIBC World Markets analyst John Zamparo has downgraded Aurora Cannabis to "underperformer" from "neutral." The Globe's David Leeder writes in the Eye On Equities column that Mr. Zamparo also trimmed his share target to $9 from $15. Analysts on average target the shares at $12.58. Mr. Zamparo says in a note: "Since March 1, Aurora's negative 26-per-cent performance exceeds the negative 33-per-cent median among closest peers. This is despite two observations. First, Hifyre data estimates that Aurora's retail sales declined approximately 21 per cent in the three months ended April 30. While this data is imperfect (it has little visibility into Quebec, and retail sales are not necessarily predictive of wholesale), this decline directionally is well below most peers, as shown herein. Second, while yet another competitor -- Organigram -- has connected with a strategic partner, Aurora finds itself lacking in this regard, while also carrying the most net debt among our cannabis coverage, and we believe is moving further away from profitability. We expect until one of these attributes reverses, Aurora will underperform other cannabis stocks."
© 2021 Canjex Publishing Ltd. All rights reserved.